ArticleProceedings of the National Academy of Sciences of the United States of America2020
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Biomaterial engineering of the tumor glycocalyx for cancer immunotherapy.Materials today. Bio · 2026Review
- Review
- Enhancing CAR-T cell activity prediction via fine-tuning protein language models with generated CAR sequences.BMC bioinformatics · 2026Article
- Review
- Targeting the cancer glycocalyx in salivary duct carcinoma: tumor-associated mucin 1 (Tn-MUC1) as a novel cell surface marker.The journal of pathology. Clinical research · 2025Article
- Tracing the development of CAR-T cell design: from concept to next-generation platforms.Frontiers in immunology · 2025Review
- Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders.Nature biomedical engineering · 2024Article
- Evolution and synthetic biology.Current opinion in microbiology · 2023Review
- Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Deep mutational scanning of proteins in mammalian cells.Cell reports methods · 2023Review
- Bringing cell therapy to tumors: considerations for optimal CAR binder design.Antibody therapeutics · 2023Review
- PASCAR: a multiscale framework to explore the design space of constitutive and inducible CAR T cells.Life science alliance · 2023Article
- Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.Journal of translational medicine · 2023Review
- Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.Journal for immunotherapy of cancer · 2023Article
- Toward high-throughput engineering techniques for improving CAR intracellular signaling domains.Frontiers in bioengineering and biotechnology · 2023Article
- Article
- A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022Review
- CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.Journal of experimental & clinical cancer research : CR · 2022Review
- Review
- Yeast Surface Display: New Opportunities for a Time-Tested Protein Engineering System.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
The potency of adoptive T cell therapies targeting the cell surface antigen CD19 has been demonstrated in hematopoietic cancers. It has been difficult to identify appropriate targets in nonhematopoietic tumors, but one class of antigens that have shown promise is aberrant O-glycoprotein epitopes. It has long been known that dysregulated synthesis of O-linked (threonine or serine) sugars occurs in many cancers, and that this can lead to the expression of cell surface proteins containing O-glycans comprised of a single
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.